Founded by Professor Peter Jenner and focusing on neurodegenerative disease, the company plans to pull in up to £12 million from institutions to finance its drug development programmes in Parkinson’s and Alzheimer’s diseases.

AIM-quoted IP2IPO, the university technology IP counter fronted by chess expert David Norwood, holds a pre-placing 46.1 per cent.

KBC Peel Hunt will act as broker and adviser.

For further information visit:

• Proximagen
• IP2IPO